Chemical proteomics and its application to drug discovery.
The completion of the human genome sequencing project has provided a flood of new information that is likely to change the way scientists approach the study of complex biological systems. A major challenge lies in translating this information into new and better ways to treat human disease. The multidisciplinary science of chemical proteomics can be used to distill this flood of new information. This approach makes use of synthetic small molecules that can be used to covalently modify a set of related enzymes and subsequently allow their purification and/or identification as valid drug targets. Furthermore, such methods enable rapid biochemical analysis and small-molecule screening of targets thereby accelerating the often difficult process of target validation and drug discovery.
Jeffery
Douglas A
DA
Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA. doug.jeffery@celera.com
Bogyo
Matthew
M
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004798:Enzymes / Q000032:analysis / Q000138:chemical synthesis / Q000737:chemistry* / Q000302:isolation & purification; D015336:Molecular Probe Techniques; D015335:Molecular Probes / Q000138:chemical synthesis* / Q000737:chemistry / Q000145:classification; D040901:Proteomics / Q000295:instrumentation / Q000379:methods*
D004798:Enzymes; D015335:Molecular Probes